Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids

Fan, Yingzi; Mu, Yandong; Lu, Lian; Tian, Yaomei; Yuan, Fengjiao; Zhou, Bailing; Yu, Chun-Hong; Wang, Zhenling; Li, Xiaolu; Song, Lei; Xu, Ying; Wu, Dongming; Yang, Li

doi:10.1016/j.intimp.2019.01.055

Cited by 16 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our epitope recognition studies showed significantly higher binding of various mAbs to the MCOdetoxified toxins compared to formaldehyde-detoxified ones, indicating that the epitopes were closer to the native state (Table 3 and 4). This is supported by previous studies showing that oxidation-based detoxification of toxins, bacteria and viruses are significantly more epitope-conserving than formaldehyde [38,76,77]. We, therefore, believe that this issue is caused by some other factor(s) than direct modifications of key epitopes by MCO, and further optimization of our MCO-detoxification method is likely needed.…”

Section: Efficacy Of Oxidatively Modified Tcda and Tcdb Vaccine In Micesupporting

confidence: 66%

“…Finally, we also determined that the molar ratios of 1:60:1000 for TcdA/B:Cu 2+ :H2O2 respectively, were optimal for the MCO components to achieve efficient detoxification of TcdA and TcdB. The concentration of H2O2 in our MCO system is at least 100-fold lower than previously reported for detoxification of Pertussis toxin [75] and whole-cell bacteria [76], and around 1000-fold lower than a hydrogen peroxide-detoxified viral vaccine [77]. Thus, the method described here for detoxification of TcdA and TcdB is orders of magnitude more efficient compared to previously used oxidation methods.…”

Section: Acidification Induced Open Conformation and Cu 2+ Catalyzed Oxidation Of Tcda And Tcdbmentioning

confidence: 79%

See 1 more Smart Citation

Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile

Aminzadeh

Tiwari

Mustapha

et al. 2020

Free Radical Biology and Medicine

View full text Add to dashboard Cite

Section: Efficacy Of Oxidatively Modified Tcda and Tcdb Vaccine In Micesupporting

confidence: 66%

Section: Acidification Induced Open Conformation and Cu 2+ Catalyzed Oxidation Of Tcda And Tcdbmentioning

confidence: 79%

Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile

Aminzadeh

Tiwari

Mustapha

et al. 2020

Free Radical Biology and Medicine

View full text Add to dashboard Cite

“…Recently, the use of H 2 O 2 to deactivate P. aeruginosa strains showed potential, resulting in reduced toxicity and retention of more complete epitopes compared to formaldehyde deactivation. Indeed, it stimulated opsonic protection (IgG1 and IgG2a) and induced IgG3 at later stages and IgM at earlier stages in mice [184].…”

Section: Whole-cell Killed and Live-attenuated P Aeruginosa Vaccinesmentioning

confidence: 95%

Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine

Sainz-Mejías

Jurado‐Martín

McClean

2020

Cells

View full text Add to dashboard Cite

Pseudomonas aeruginosa is a leading cause of chronic respiratory infections in people with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and acute infections in immunocompromised individuals. The adaptability of this opportunistic pathogen has hampered the development of antimicrobial therapies, and consequently, it remains a major threat to public health. Due to its antimicrobial resistance, vaccines represent an alternative strategy to tackle the pathogen, yet despite over 50 years of research on anti-Pseudomonas vaccines, no vaccine has been licensed. Nevertheless, there have been many advances in this field, including a better understanding of the host immune response and the biology of P. aeruginosa. Multiple antigens and adjuvants have been investigated with varying results. Although the most effective protective response remains to be established, it is clear that a polarised Th2 response is sub-optimal, and a mixed Th1/Th2 or Th1/Th17 response appears beneficial. This comprehensive review collates the current understanding of the complexities of P. aeruginosa-host interactions and its implication in vaccine design, with a view to understanding the current state of Pseudomonal vaccine development and the direction of future efforts. It highlights the importance of the incorporation of appropriate adjuvants to the protective antigen to yield optimal protection.

show abstract

“…They are attractive candidate formulations, as pathogen-associated molecular patterns (PAMPs) act as adjuvants and the cell corpuscles function as delivery systems for a range of protective antigens [ 86 ]. Hydrogen peroxide bacterial inactivation is associated with reduced toxicity, overall increased immunogenicity, and more diverse immune response when compared with formaldehyde inactivation [ 87 ]. Novel X-ray inactivated whole-cell P. aeruginosa vaccine greatly boosted cell-mediated immune responses, Th1 and Th2 cytokine profiles, and protected against multiple strains of P. aeruginosa [ 88 ].…”

Section: New Developments In P Aeruginosa Vaccinologymentioning

confidence: 99%

Pseudomonas aeruginosa: Recent Advances in Vaccine Development

2022

View full text Add to dashboard Cite

Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of P. aeruginosa clinical infections and its major important virulence factors.

show abstract

Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids

Cited by 16 publications

References 38 publications

Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile

Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile

Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine

Pseudomonas aeruginosa: Recent Advances in Vaccine Development

Contact Info

Product

Resources

About